Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IEUR | 76.57 | 2.23 | +3.00% |
| iShares Core MSCI Europe ETF (IEUR) | |||
| TDVI | 31.04 | 0.24 | +0.78% |
| FT Vest Technology Dividend Target Income ETF (TDVI) | |||
| EZJ | 62.07 | N/A | N/A |
| ProShares Ultra MSCI Japan (EZJ) | |||
| CCRP | 18.73 | N/A | N/A |
| Columbia Corporate Bond ETF | |||
| TZA | 44.52 | -2.06 | -4.42% |
| Direxion Daily Small Cap Bear 3X ETF (TZA) | |||
A.I.dvisor indicates that over the last year, CHE has been loosely correlated with UHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CHE jumps, then UHS could also see price increases.
| Ticker / NAME | Correlation To CHE | 1D Price Change % | ||
|---|---|---|---|---|
| CHE | 100% | +2.81% | ||
| UHS - CHE | 43% Loosely correlated | +10.91% | ||
| PNTG - CHE | 33% Poorly correlated | +6.92% | ||
| ENSG - CHE | 32% Poorly correlated | +3.35% | ||
| OPCH - CHE | 32% Poorly correlated | -0.38% | ||
| NHC - CHE | 24% Poorly correlated | +3.19% | ||
More | ||||
| Ticker / NAME | Correlation To CHE | 1D Price Change % |
|---|---|---|
| CHE | 100% | +2.81% |
| Hospital/Nursing Management industry (48 stocks) | 20% Poorly correlated | -2.16% |
a holding medical company
Industry HospitalNursingManagement
CHE saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 55 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 60%.
The Moving Average Convergence Divergence (MACD) for CHE just turned positive on October 14, 2026. Looking at past instances where CHE's MACD turned positive, the stock continued to rise in 27 of 51 cases over the following month. The odds of a continued upward trend are 53%.
CHE moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHE advanced for three days, in 159 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 76 of 200 cases where CHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.
The 10-day RSI Indicator for CHE moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 28 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 69 cases where CHE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
CHE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 36 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. CHE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.634) is normal, around the industry mean (204.059). P/E Ratio (27.584) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (1.876) is also within normal values, averaging (2.498). Dividend Yield (0.005) settles around the average of (0.091) among similar stocks. P/S Ratio (2.714) is also within normal values, averaging (2.688).